In experimental models, oligoclonal cocktails of three (32, 33) to six (34, 35) antibodies against EGFR, HER2 and HER3 increased the anti-tumor effect with blockade of the intracellular ERK and AKT signaling pathways and accelerated receptor degradation. Here, ERBB2 is linked to neoplasm.